Evidence map›Paper›PMID 36591564›Full record

ReviewNano research2023

Native and engineered exosomes for inflammatory disease.

Xiaoyi Ma, Bingbing Liu, Limin Fan, Yiqiong Liu, Yuge Zhao, Tianbin Ren, Yan Li, Yongyong Li

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nano research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Exosomal miRNAs: A New Frontier in Cardiovascular Disease Diagnosis and Treatment.Journal of cardiovascular translational research · 2025
    Review
  15. Progress in Neck Rejuvenation Injection Therapy.Aesthetic plastic surgery · 2025
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Xiaoyi Ma *Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, 200092 China.
Bingbing Liu *Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, 200092 China.
Limin FanShanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, 200092 China.
Yiqiong LiuShanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, 200092 China.
Yuge ZhaoShanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, 200092 China.
Tianbin RenShanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, 200092 China.
Yan LiShanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, 200092 China.
Yongyong LiShanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, 200092 China.
Shanghai Skin Disease Hospital · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exosomes are extracellular vesicles which carry specific molecular information from donor cells and act as an intercellular communication vehicle, which have emerged as a novel cell-free strategy for the treatment of many diseases including inflammatory disease. Recently, rising studies have developed exosome-based strategies for novel inflammation therapy due to their biocompatibility and bioactivity. Researchers not only use native exosomes as therapeutic agents for inflammation, but also strive to make up for the natural defects of exosomes through engineering methods to improve and update the property of exosomes for enhanced therapeutic effects. The engineered exosomes can improve cargo-loading efficiency, targeting ability, stability, etc., to achieve combined and diverse treatment strategies in inflammation diseases. Herein, a comprehensive overview of the recent advances in application studies of native and engineered exosomes as well as the engineered methods is provided. Meanwhile, potential application prospects, possible challenges, and the development of clinical researches of exosome treatment strategy are concluded from plentiful examples, which may be able to provide guidance and suggestions for the future research and application of exosomes.

Indexed as

engineered exosomeexosomeexosomes-based therapyinflammation

Identifiers

PMID36591564
PMCPMC9793369
OpenAlexW4313256758

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.